Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

NCRI 2013 /
Polygenic susceptibility: What might it tell us?

3rd - 6th Nov 2013

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.11.13
Views: 2745
Rating:

Sir Bruce Ponder - University of Cambridge, UK

Prof Ponder talks to ecancertv at the UK's National Cancer Research Institute ( NCRI ) 2013 meeting where he received the Lifetime Achievement award.

Prof Ponder's first major success in genetics was the linkage of medullary thyroid cancer to chromosome 10, which led to a test for genetic susceptibility to this rare disease.

In the late 1980s he moved on to study breast cancer; the international consortium he established  in breast cancer genetics led directly to the discovery of BRCA1 and BRCA2.

Later still he was involved in the first genome-wide association scans (GWAS).

Results from these, however, have been disappointing: for example, even with GWAS we have been able to explain less than 20% of the genetic variation in breast cancer risk.

Ponder ended his plenary lecture by suggesting that combining genes into networks might help explain some of this missing heritability of breast cancer.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation